Clinical Trial Update: Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of vebotolimab and Ptorlimab for EGFR-positive advanced biliary tract cancers is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• Ptorlimab
• Vebotolimab

Snippet

Sponsor: West China Hospital | Conditions: Cancer of Biliary Duct | Phase 2 | Status: NOT_YET_RECRUITING